Journal: Stem Cells Translational Medicine

Article Title: Extracellular Vesicles From Mesenchymal Umbilical Cord Cells Exert Protection Against Oxidative Stress and Fibrosis in a Rat Model of Bronchopulmonary Dysplasia

doi: 10.1093/stcltm/szad070

Figure Lengend Snippet: Antibody list.

Article Snippet: Goat anti RAGE , AF1145 , BIO-TECHNE.

Techniques:

Journal: Cardiovascular Diabetology

Article Title: Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study

doi: 10.1186/s12933-022-01535-3

Figure Lengend Snippet: Comparison of AGEs, sRAGE isoforms, and their ratios between healthy controls (CTR) and patients with type 2 diabetes

Article Snippet: Specifically, total human sRAGE included the detection of both cRAGE and esRAGE variants (DY1145, Human RAGE DuoSet ELISA, R&D Systems Inc., MN, USA) and esRAGE concentration was evaluated by an ELISA assay with an antibody raised against the exclusive C-terminal amino acids (332–347) sequence (K1009-1, B-bridge International, CA, USA). cRAGE was determined by subtracting esRAGE from sRAGE as already described [ , , ].

Techniques: Comparison

Journal: Cardiovascular Diabetology

Article Title: Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study

doi: 10.1186/s12933-022-01535-3

Figure Lengend Snippet: Boxplots for the comparison of A total sRAGE, esRAGE, and cRAGE isoforms and ) AGEs/sRAGE, AGEs/esRAGE, AGEs/cRAGE, cRAGE/esRAGE ratio among healthy control subjects (CTR) and type 2 diabetes patients without (T2DM-NC) or with (T2DM-C) complications. **p < 0.01; ***p < 0.001; ****p < 0.0001 for Dunn’s post-hoc tests following Kruskal-Wallis H test

Article Snippet: Specifically, total human sRAGE included the detection of both cRAGE and esRAGE variants (DY1145, Human RAGE DuoSet ELISA, R&D Systems Inc., MN, USA) and esRAGE concentration was evaluated by an ELISA assay with an antibody raised against the exclusive C-terminal amino acids (332–347) sequence (K1009-1, B-bridge International, CA, USA). cRAGE was determined by subtracting esRAGE from sRAGE as already described [ , , ].

Techniques: Comparison, Control

Journal: Cardiovascular Diabetology

Article Title: Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study

doi: 10.1186/s12933-022-01535-3

Figure Lengend Snippet: Spearman correlations of AGEs and the different isoforms of sRAGE isoforms with age in healthy controls (CTR) and patients with type 2 diabetes

Article Snippet: Specifically, total human sRAGE included the detection of both cRAGE and esRAGE variants (DY1145, Human RAGE DuoSet ELISA, R&D Systems Inc., MN, USA) and esRAGE concentration was evaluated by an ELISA assay with an antibody raised against the exclusive C-terminal amino acids (332–347) sequence (K1009-1, B-bridge International, CA, USA). cRAGE was determined by subtracting esRAGE from sRAGE as already described [ , , ].

Techniques:

Journal: Cardiovascular Diabetology

Article Title: Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study

doi: 10.1186/s12933-022-01535-3

Figure Lengend Snippet: Age- and HbA1c-adjusted multiple quantile regression model for the evaluation of AGEs and sRAGE isoforms in type 2 diabetes complications

Article Snippet: Specifically, total human sRAGE included the detection of both cRAGE and esRAGE variants (DY1145, Human RAGE DuoSet ELISA, R&D Systems Inc., MN, USA) and esRAGE concentration was evaluated by an ELISA assay with an antibody raised against the exclusive C-terminal amino acids (332–347) sequence (K1009-1, B-bridge International, CA, USA). cRAGE was determined by subtracting esRAGE from sRAGE as already described [ , , ].

Techniques:

Journal: Cardiovascular Diabetology

Article Title: Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study

doi: 10.1186/s12933-022-01535-3

Figure Lengend Snippet: Univariate and multivariate Cox regression analysis for the prediction of 15-year all-cause mortality in patients with type 2 diabetes

Article Snippet: Specifically, total human sRAGE included the detection of both cRAGE and esRAGE variants (DY1145, Human RAGE DuoSet ELISA, R&D Systems Inc., MN, USA) and esRAGE concentration was evaluated by an ELISA assay with an antibody raised against the exclusive C-terminal amino acids (332–347) sequence (K1009-1, B-bridge International, CA, USA). cRAGE was determined by subtracting esRAGE from sRAGE as already described [ , , ].

Techniques:

Journal: Experimental and Therapeutic Medicine

Article Title: Epigallocatechin-3-gallate attenuates neointimal hyperplasia in a rat model of carotid artery injury by inhibition of high mobility group box 1 expression

doi: 10.3892/etm.2017.4774

Figure Lengend Snippet: EGCG inhibits balloon injury-induced HMGB1 and RAGE expression levels. mRNA expression levels of (A) HMGB1 and (B) RAGE in artery tissues were determined by reverse transcription-quantitative polymerase chain reaction. Protein expression levels of (C) HMGB1 and (D) RAGE in artery tissues were detected by western blotting. β-actin was used as a loading control. The protein bands were quantified by gray scanning. Data are presented as the mean + standard deviation (n=6). *P<0.05, **P<0.01 and ***P<0.001 vs. the sham group; # P<0.05, ## P<0.01 and ### P<0.001 vs. the injury group. EGCG, epigallocatechin-3-gallate; HMGB1, high mobility group box 1; RAGE, receptor of advanced glycation end products.

Article Snippet: Subsequent to blocking with 5% skimmed milk for 1 h at room temperature, the membranes were incubated with primary antibodies against HMGB1 (Boster Biological Technology, Ltd., Wuhan, China; catalogue no. BA4277; 1:400), RAGE (Boster Biological Technology, Ltd.; catalogue no. PB0530; 1:400), nuclear factor (NF)-κB (Boster Biological Technology, Ltd.; catalogue no. BA0610; 1:400) and β-actin (Santa Cruz Biotechnology, Dallas, USA; catalogue no. sc-47778; 1:400), respectively at 4°C overnight.

Techniques: Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction, Western Blot, Control, Standard Deviation